d'Andrea Giacomo, Mancusi Gianluca, Santovito Maria Chiara, Marrangone Carlotta, Martino Fabrizio, Santorelli Mario, Miuli Andrea, Di Carlo Francesco, Signorelli Maria Salvina, Clerici Massimo, Pettorruso Mauro, Martinotti Giovanni
Department of Neurosciences, Imaging and Clinical Sciences, Università degli Studi G. D'Annunzio, 66100 Chieti, Italy.
Psychiatric Residency Training Program, School of Medicine and Surgery, University of Milano Bicocca, 20900 Monza, Italy.
J Pers Med. 2023 Apr 21;13(4):697. doi: 10.3390/jpm13040697.
Repetitive Transcranial Magnetic Stimulation (rTMS) has been approved by the FDA as an effective intervention for Treatment-Resistant Depression (TRD). However, there is little evidence about maintenance protocol necessity. The aim of this systematic review is to identify, characterize, and evaluate the current maintenance TMS protocols for MDD and TRD patients who have received acute treatment. A literature search was conducted following the PRISMA guidelines of 2015 on PubMed, Scopus, and Web of Science databases for publications up to March 2022. Fourteen articles were included. High protocol heterogeneity was observed. Most studies highlighted significant efficacy of maintenance protocols in decreasing relapse risk, suggesting that administering two or fewer stimulations per month is ineffective in sustaining an antidepressant effect or in reducing the risk of relapse in responder patients. The risk of relapse was most pronounced after five months from the acute treatment. Maintenance TMS appears to be a resourceful strategy to maintain acute antidepressant treatment effects, significantly reducing relapse risk. The ease of administering and the ability to monitor treatment adherence should be considered when evaluating the future use of maintenance TMS protocols. Further studies are needed to clarify the clinical relevance of overlapping acute TMS effects with maintenance protocols and to evaluate their long-term effectiveness.
重复经颅磁刺激(rTMS)已被美国食品药品监督管理局(FDA)批准为治疗难治性抑郁症(TRD)的有效干预措施。然而,关于维持方案必要性的证据很少。本系统评价的目的是识别、描述和评估目前针对接受过急性期治疗的重度抑郁症(MDD)和TRD患者的维持性经颅磁刺激方案。按照2015年PRISMA指南,于2022年3月前在PubMed、Scopus和科学网数据库中进行文献检索。纳入了14篇文章。观察到方案的高度异质性。大多数研究强调维持方案在降低复发风险方面具有显著疗效,表明每月给予两次或更少的刺激对于维持抗抑郁效果或降低缓解期患者的复发风险无效。复发风险在急性期治疗五个月后最为明显。维持性经颅磁刺激似乎是维持急性期抗抑郁治疗效果、显著降低复发风险的有效策略。在评估维持性经颅磁刺激方案的未来应用时,应考虑给药的便利性和监测治疗依从性的能力。需要进一步研究来阐明急性期经颅磁刺激效果与维持方案重叠的临床相关性,并评估其长期有效性。